Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Oct 15;13(12):3210–3218. doi: 10.1158/1535-7163.MCT-14-0349

Figure 4.

Figure 4

Blood BRAFV600E levels in 18 patients with BRAFV600E melanoma treated with either vemurafenib (12 patients) or the combination of dabrafenib and trametinib (6 patients) dramatically reduce following the commencement of therapy. The data in (A) show the response of individual patients to the drug regimen. (B) Mean BRAFV600E levels in response to either vemurafenib or the dabrafenib and trametinib combination. The values in (B) are relative to pretreatment levels (set as 1.0).